Stavudine

• CAT Number: A000656
• CAS Number: 3056-17-5
• Molecular Formula: C10H12N2O4
• Molecular Weight: 224.2
• Purity: ≥95%
• Target: HIV
• Solubility: >8.4mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
• InChIKey: XNKLLVCARDGLGL-JGVFFNPUSA-N
• SMILES: CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO

Stavudine s an antiretroviral medication used to prevent and treat HIV/AIDS.[1] It is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class.

Reference

1: Cassim H, Otwombe K, Lazarus E, Liberty A, Gray GE, Greeff OBW, Violari A. A
retrospective case-cohort study comparing treatment outcomes in abacavir versus
stavudine containing first line antiretroviral treatment regimens in children
<3yrs old, at a paediatric programme based in Soweto, South Africa. PLoS One.
2017 Jul 7;12(7):e0180645. doi: 10.1371/journal.pone.0180645. eCollection 2017.
PubMed PMID: 28686654; PubMed Central PMCID: PMC5501584.

2: Conradie MM, van de Vyver M, Andrag E, Conradie M, Ferris WF. A Direct
Comparison of the Effects of the Antiretroviral Drugs Stavudine, Tenofovir and
the Combination Lopinavir/Ritonavir on Bone Metabolism in a Rat Model. Calcif
Tissue Int. 2017 May 20. doi: 10.1007/s00223-017-0290-3. [Epub ahead of print]
PubMed PMID: 28528404.

3: Nayak D, Boxi A, Ashe S, Thathapudi NC, Nayak B. Stavudine loaded gelatin
liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic
evaluation. Mater Sci Eng C Mater Biol Appl. 2017 Apr 1;73:406-416. doi:
10.1016/j.msec.2016.12.073. Epub 2016 Dec 16. PubMed PMID: 28183626.

4: Singh A, Hemal A, Agarwal S, Dubey NK, Buxi G. A prospective study of
haematological changes after switching from stavudine to zidovudine-based
antiretroviral treatment in HIV-infected children. Int J STD AIDS. 2016
Nov;27(13):1145-1152. Epub 2014 Feb 10. PubMed PMID: 24516076.

5: Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, Prozesky H,
Tanser F, Fatti G, Boulle A, Sikazwe I, Wool-Kaloustian K, Yuannoutsos C, Leroy
V, de Rekeneire N, Fox MP. Has the phasing out of stavudine in accordance with
changes in WHO guidelines led to a decrease in single-drug substitutions in
first-line antiretroviral therapy for HIV in sub-Saharan Africa? AIDS. 2017 Jan
2;31(1):147-157. PubMed PMID: 27776039; PubMed Central PMCID: PMC5137584.

6: Marwaha L, Bansal Y, Singh R, Saroj P, Sodhi RK, Kuhad A. Niflumic acid, a
TRPV1 channel modulator, ameliorates stavudine-induced neuropathic pain.
Inflammopharmacology. 2016 Dec;24(6):319-334. Epub 2016 Oct 18. PubMed PMID:
27757590.

7: Ghosh S, Mondal L, Chakraborty S, Mukherjee B. Early Stage HIV Management and
Reduction of Stavudine-Induced Hepatotoxicity in Rats by Experimentally Developed
Biodegradable Nanoparticles. AAPS PharmSciTech. 2017 Apr;18(3):697-709. doi:
10.1208/s12249-016-0539-6. Epub 2016 May 24. PubMed PMID: 27222026.

8: van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA,
Wiersinga WJ, Prins M, van den Born BJ, Reiss P; AGEhIV Cohort Study Group.
Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination
Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior
Stavudine Exposure. Clin Infect Dis. 2016 Jul 15;63(2):205-13. doi:
10.1093/cid/ciw285. Epub 2016 May 3. PubMed PMID: 27143668.

9: Adebiyi OO, Adebiyi OA, Owira P. Naringin improves zidovudine- and
stavudine-induced skeletal muscle complications in rats. Hum Exp Toxicol. 2016
Mar 22. pii: 0960327116638726. [Epub ahead of print] PubMed PMID: 27005762.

10: Vidyadhara S, Sasidhar RL, Balakrishna T, Balaji B, Amrutha R. Formulation
and Evaluation of Controlled Release Floating Microballoons of Stavudine. Sci
Pharm. 2015 Jun 9;83(4):671-82. doi: 10.3797/scipharm.1501-07. Print 2015
Oct-Dec. PubMed PMID: 26839847; PubMed Central PMCID: PMC4727757.